Alira Health

The Medical Plastics Imperative for CDMOs: Sustainable, Scalable, Specialized

The Medical Plastics Imperative for CDMOs: Sustainable, Scalable, Specialized

In 2025, contract development and manufacturing organizations (CDMOs) have become vital strategic partners for original equipment manufacturers (OEMs) aiming to accelerate product development and secure resilient production pipelines. The global medtech outsourcing market grew to $89 billion in 2024, highlighting growing OEM reliance on CDMOs.

One of the fastest-growing segments is medical plastics, fueled by the increasing demand for sustainable manufacturing, rapid advances in material science, and continued expansion in the medtech sector. These materials are evolving to be bioabsorbable, recyclable, and high-performance, delivering both sustainability and reliability in applications such as catheters, syringes, surgical tools, and drug delivery devices.

Driven by this demand, the global medical plastics market, valued at $31.7 billion in 2024, is projected to reach $44 billion by 2029, reflecting strong demand for innovative, eco-conscious materials and manufacturing methods.

This article explores three strategic growth opportunities for plastics-based device manufacturers in 2025, outlines key market challenges, and defines what it takes for CDMOs to lead in this evolving space.

Three Axes of Growth in Medical Plastics

Material Selection

Plastics developers are advancing biodegradable and antimicrobial materials to meet performance and sustainability goals. High performance polymers such as polyether ether ketone (PEEK) and polyetherimide (PEI) are rapidly gaining traction due to their superior properties and sterilization resistance, critical for applications like surgery and implant components.

The increasing focus on sustainability is evident in the adoption of biodegradable materials for disposable medical devices and packaging, aligning with the steady growth trajectory fueled by eco-friendly innovations. Antimicrobial plastics are also essential for infection control in healthcare settings. With rising awareness of hospital acquired infections, the demand for these materials is increasing in both reusable and disposable devices.

Capabilities Offered

Device manufacturers seek to acquire miniaturization, rapid prototyping, and advanced manufacturing techniques. The demand for minimally invasive medical procedures accelerates the development of ultrasmall components through micro molding, a specialized form of injection molding capable of producing ultra-small medical components.

The adoption of simulation technologies and additive manufacturing (3D printing) has accelerated the development of medical devices, enabling faster prototyping, design iteration, and customization. These advancements result in a more efficient product development cycle, reducing time-to-market and fostering innovation.

Advanced manufacturing techniques such as micro molding, laser cutting, and extrusion address the need for high-volume, high-precision, and complex medical device production. These capabilities are key enablers to meet growing demand and support expanding applications.

Adaptability in End Markets Served

The increasing demand for plastics is evident across multiple medical applications, particularly in disposable medical devices, surgical instruments, drug delivery systems, and implantable solutions. Disposable devices like syringes, IV bags, and catheters are experiencing high demand due to their role in infection prevention and one-time use. This demand does raise sustainability concerns versus reusables, but innovation in biodegradable materials and scalable recycling solutions is also growing.

Medical plastics are replacing traditional materials in surgical tools, offering benefits like lightweight designs, cost-efficiency, and improved sterility. High-performance polymers, particularly PEEK and PEI, are increasingly used in minimally invasive surgical and implantable devices due to their biocompatibility and strength.

Medical plastics are integral to the production of drug delivery systems such as insulin pens, inhalers, and transdermal patches. Given the rise of chronic disease prevalence worldwide, these methods of drug delivery are critical. Biocompatible and precision-molded plastics ensure safety and functionality.

The prosthetics and implants market is shifting towards high-performance and biocompatible polymers (e.g., PEEK and PEI for implants and prosthetic applications, bioresorbable polymers for prosthetics and orthopedic implants). These materials provide enhanced durability, biocompatibility, and patient outcomes, fueling their adoption.

Key Challenges in the Medical Plastics Market

The medical plastics market is growing, but sustaining momentum will depend on overcoming supply chain disruptions and heightened regulatory pressures, while maintaining a competitive edge through innovation and efficiency.

One challenge is the complexity found in navigating multi-tiered supply chains. The medical plastics market operates within a highly fragmented supply chain that includes multiple layers of suppliers and raw material sources. Supply disruptions, caused by geopolitical tensions or trade barriers, have resulted in a constrained supply of specialized medical-grade resins. This dynamic is driving up raw material costs, impacting production schedules.

The medical device industry also faces increased scrutiny regarding its environmental footprint, with growing pressure to address plastic waste. This is leading to bans on certain single-use plastics and calls for end-of-life recycling solutions. However, the challenge lies in developing scalable recycling methods for medical-grade materials.

Price pressures are also an issue. Governments control healthcare facility spending, putting pressure on prices across the entire medical device value chain. Rising raw material costs significantly impact gross margins. As a result, OEMs and CDMOs work with several selected suppliers, negotiating to secure the best possible prices.

Finally, high-performance polymers are difficult to manufacture (e.g., PEEK’s viscosity and polyphenylene sulfide’s highly semi-crystalline nature and thermal crosslinking in material extrusion) and expensive. As a result, their use in the medical plastic market is limited to applications where no substitutes are viable, typically in high-end low-volume devices.

Success Factors for Medical Plastics CDMOs

OEMs are looking for end-to-end solutions partners who can handle the entire production process from raw material sourcing and design to manufacturing and delivery. CDMOs must have cutting-edge expertise in advanced techniques like micro- molding, insert molding, and precision extrusion, critical to manufacturing highly complex, miniaturized components required for modern medical devices.

A CDMO’s history of successfully delivering specialized, high-stakes projects can be a decisive factor for OEM clients. Outsourcing firms should demonstrate expertise in sourcing raw materials, navigating complex regulatory requirements, handling precision manufacturing, delivering products on time, and meeting project-specific needs. A strong, transparent supply chain with built-in contingencies ensures OEMs can depend on CDMOs for consistent production. With a global shift toward eco-friendly manufacturing, CDMOs must embrace biodegradable and recyclable materials, energy-efficient processes, and waste reduction techniques.

Conclusion

CDMOs have evolved into essential strategic partners for OEMs, reflecting the significant growth of the global medtech outsourcing market, which reached $89 billion in 2024. Within medtech, medical plastics is one of the major growth segments, supported by ongoing advances in sustainable and high-performance materials alongside expanding applications across disposable devices, surgical tools, and implantable technologies.

This evolving landscape presents both opportunities and challenges. Despite strong growth, industry players still need to navigate complex supply chains, regulatory pressures, and cost constraints, especially when working with specialized, high-performance materials.

For CDMOs, success requires a comprehensive, end-to-end approach, from material sourcing to manufacturing excellence, combined with robust supply chain management and a commitment to sustainability. Similarly, OEMs partnering with CDMOs that can deliver these capabilities will be well positioned to accelerate product development, manage risk, and capitalize on emerging opportunities in the rapidly evolving medical plastics market.

Access the 2026 Global Medtech Contract Development and Manufacturing Report for more insights into this market.

Expert insights
provided by:

Sofia Puzzi

Sofia Puzzi, Principal, Transaction Advisory

Eve Ogdon, Consultant, Management Consulting

Mololuwa Oluwajobi, Senior Associate, Transaction Advisory

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.